Get the Stockscreener App
43.24
0.86%
-0.036
Anaptysbio Inc stock is traded at $43.24, with a volume of 60,021.
It is down -0.86% in the last 24 hours and down -3.43% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$43.20
Open:
$42.46
24h Volume:
60,021
Relative Volume:
0.12
Market Cap:
$1.21B
Revenue:
$17.16M
Net Income/Loss:
$-163.62M
P/E Ratio:
-7.1112
EPS:
-6.08
Net Cash Flow:
$-121.61M
1W Performance:
-11.20%
1M Performance:
-3.43%
6M Performance:
+80.34%
1Y Performance:
+179.93%
1-Day Range:
$42.00
$43.57
1-Week Range:
$42.00
$49.19
52-Week Range:
$12.21
$52.47
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
43.57 | 1.20B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.71 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.49 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.77 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.47 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio, Inc. $ANAB Shares Sold by Voya Investment Management LLC - MarketBeat
Is AnaptysBio Inc AN6 a good long term investmentTrading Volume Surges & High Profit Investment Ideas - earlytimes.in
New Highs: Is AnaptysBio Inc stock a safe haven assetEarnings Growth Report & AI Forecasted Stock Moves - moha.gov.vn
This biotech stock has more than tripled in 2025, but red flags are waving - MSN
AnaptysBio (NASDAQ:ANAB) Stock Price Down 4%Should You Sell? - MarketBeat
Trade Alert: Independent Director Of AnaptysBio J. Ware Has Sold Stock - simplywall.st
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at $51.58 - Investing.com
AnaptysBio stock hits 52-week high at $51.58 By Investing.com - Investing.com Canada
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 3,900 Shares of Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Sells $75,000.00 in Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Dennis Mulroy Sells 10,000 Shares - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 10,000 Shares - MarketBeat
Anaptysbio Insider Sold Shares Worth $510,000, According to a Recent SEC Filing - marketscreener.com
Anaptysbio Insider Sold Shares Worth $500,000, According to a Recent SEC Filing - marketscreener.com
AnaptysBio Executives and Director Execute Stock Sales - TradingView — Track All Markets
AnaptysBio Executives Sell Shares - TradingView — Track All Markets
AnaptysBio (NASDAQ: ANAB) CMO reports option exercise and stock sale - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is AnaptysBio Inc. stock a buy in volatile marketsDip Buying & AI Enhanced Market Trend Forecasts - Улправда
AnaptysBio sets $100M stock repurchase plan - MSN
How AnaptysBio Inc. (AN6) stock trades under stagflationJuly 2025 Spike Watch & Smart Allocation Stock Reports - Улправда
This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving - Yahoo Finance
Will AnaptysBio Inc. stock reach Wall Street targetsQuarterly Market Review & Consistent Income Trade Recommendations - DonanımHaber
What dividend safety score for AnaptysBio Inc. stockNew Guidance & Consistent Growth Stock Picks - Bölüm Sonu Canavarı
Is AnaptysBio Inc. stock recession proofIPO Watch & Capital Efficiency Focused Strategies - DonanımHaber
AnaptysBio, Inc. $ANAB Shares Bought by Assenagon Asset Management S.A. - MarketBeat
AnaptysBio (STU:AN6) EV-to-OCF : -6.99 (As of Dec. 19, 2025) - GuruFocus
AnaptysBio (NASDAQ:ANAB) Sets New 1-Year HighWhat's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Sells $705,266.25 in Stock - MarketBeat
Eric Loumeau Sells 10,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 12,500 Shares - MarketBeat
Avoiding Lag: Real-Time Signals in (ANAB) Movement - Stock Traders Daily
AnaptysBio (ANAB) CFO option exercise and Rule 10b5-1 share sale detailed - Stock Titan
AnaptysBio stock hits 52-week high at 47.95 USD - Investing.com
AnaptysBio stock hits 52-week high at 47.95 USD By Investing.com - Investing.com Nigeria
Squarepoint Ops LLC Invests $2.43 Million in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) Receives a Buy from Wells Fargo - The Globe and Mail
AnaptysBio (ANAB) Price Target Lowered by Barclays, Maintains Ov - GuruFocus
Officer Loumeau Files To Sell 12,500 Of AnaptysBio Inc [ANAB] - TradingView — Track All Markets
Vanda submits BLA to FDA for generalized pustular psoriasis drug By Investing.com - Investing.com Nigeria
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - marketscreener.com
Vanda (Nasdaq: VNDA) seeks priority FDA review of BLA for GPP drug imsidolimab - Stock Titan
JP Morgan maintains a sell rating on GSK plc (GSK) - MSN
683 Capital Management LLC Has $11.10 Million Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Camber Capital Management LP Sells 625,000 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio stock hits 52-week high at 46.57 USD - Investing.com
AnaptysBio stock hits 52-week high at 46.57 USD By Investing.com - Investing.com Canada
Stifel Nicolaus Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $56.00 - MarketBeat
AnaptysBio (ANAB) Analyst Rating Update: Stifel Lowers Price Tar - GuruFocus
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment - BioSpace
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anaptysbio Inc Stock (ANAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lizzul Paul F. | Chief Medical Officer |
Dec 22 '25 |
Option Exercise |
18.50 |
1,500 |
27,750 |
28,467 |
| Lizzul Paul F. | Chief Medical Officer |
Dec 22 '25 |
Sale |
50.00 |
1,500 |
75,000 |
26,967 |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER |
Dec 22 '25 |
Option Exercise |
20.16 |
10,000 |
201,600 |
19,401 |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER |
Dec 22 '25 |
Sale |
50.00 |
10,000 |
500,000 |
9,401 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Dec 22 '25 |
Option Exercise |
14.02 |
10,000 |
140,200 |
18,947 |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Dec 22 '25 |
Sale |
51.00 |
10,000 |
510,000 |
8,947 |
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):